Arthur A. Hurwitz

Combination Immunotherapy of B16 Melanoma Using Anti–Cytotoxic T Lymphocyte–Associated Antigen 4 (Ctla-4) and Granulocyte/Macrophage Colony-Stimulating Factor (Gm-Csf)-Producing Vaccines Induces Rejection of Subcutaneous and Metastatic Tumors Accompanied by Autoimmune Depigmentation

Andrea van Elsas, Arthur A. Hurwitz, James P. Allison · The Journal of Experimental Medicine · 1999 · 1K citations · Full text

Medicine, Immunology, Oncology +17

Combination immunotherapy of primary prostate cancer in a transgenic mouse model using CTLA-4 blockade.

Arthur A. Hurwitz, Barbara A. Foster, Eugene D. Kwon et al. · PubMed · 2000 · 427 citations

Medicine, Immunology, Oncology +17

Manipulation of T cell costimulatory and inhibitory signals for immunotherapy of prostate cancer

Eugene D. Kwon, Arthur A. Hurwitz, Barbara A. Foster et al. · Proceedings of the National Academy of Sciences · 1997 · 393 citations

Medicine, Immunology, Oncology +17

CTLA-4 blockade synergizes with tumor-derived granulocyte– macrophage colony-stimulating factor for treatment of an experimental mammary carcinoma

Arthur A. Hurwitz, Tina F.-Y. Yu, Dana R. Leach et al. · Proceedings of the National Academy of Sciences · 1998 · 374 citations · Full text

Medicine, Immunology, Oncology +17

Elucidating the Autoimmune and Antitumor Effector Mechanisms of a Treatment Based on Cytotoxic T Lymphocyte Antigen-4 Blockade in Combination with a B16 Melanoma Vaccine

Andrea van Elsas, Roger P.M. Sutmuller, Arthur A. Hurwitz et al. · The Journal of Experimental Medicine · 2001 · 307 citations · Full text

Medicine, Immunology, Oncology +17